The National Institute of Allergy and Infectious Diseases (NIAID) announced in a statement that they have stopped clinical trials of Eli Lilly’s CCP virus antibody treatment on hospitalized patients.
This came after the Data and Safety Monitoring Board (DSMB) conducted an independent investigation and recommended that the trials be halted after discovering that Eli Lilly’s neutralizing antibody treatment isn’t likely to improve a hospitalized patient’s condition. The study was conducted on patients who were already in the later stages of COVID-19, the disease the CCP (Chinese Communist Party) virus causes.
